CN108794604B - Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof - Google Patents
Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof Download PDFInfo
- Publication number
- CN108794604B CN108794604B CN201810717782.9A CN201810717782A CN108794604B CN 108794604 B CN108794604 B CN 108794604B CN 201810717782 A CN201810717782 A CN 201810717782A CN 108794604 B CN108794604 B CN 108794604B
- Authority
- CN
- China
- Prior art keywords
- svapaaagin
- aging
- biologically active
- active polypeptide
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 94
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000975 bioactive effect Effects 0.000 title abstract description 48
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 230000007365 immunoregulation Effects 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000036541 health Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004698 lymphocyte Anatomy 0.000 abstract description 13
- 210000002540 macrophage Anatomy 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract description 12
- 238000000338 in vitro Methods 0.000 abstract description 11
- 230000032683 aging Effects 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 230000000638 stimulation Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000036737 immune function Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 241000255588 Tephritidae Species 0.000 description 29
- 239000011347 resin Substances 0.000 description 21
- 229920005989 resin Polymers 0.000 description 21
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 11
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000004957 immunoregulator effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 241000255601 Drosophila melanogaster Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000006315 carbonylation Effects 0.000 description 3
- 238000005810 carbonylation reaction Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000021523 carboxylation Effects 0.000 description 3
- 238000006473 carboxylation reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000033444 hydroxylation Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- -1 aromatic amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003226 decolorizating effect Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000012376 hot air sterilization Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZQOILFFBJUNGRA-NMVUUJPQSA-N (4s)-4-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-[(2s)-2-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C ZQOILFFBJUNGRA-NMVUUJPQSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- 102000009366 Alpha-s1 casein Human genes 0.000 description 1
- 108050000244 Alpha-s1 casein Proteins 0.000 description 1
- 108050001786 Alpha-s2 casein Proteins 0.000 description 1
- BEHQTVDBCLSCBY-CFMVVWHZSA-N Asn-Tyr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BEHQTVDBCLSCBY-CFMVVWHZSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
- MXIULRKNFSCJHT-STQMWFEESA-N Gly-Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 MXIULRKNFSCJHT-STQMWFEESA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- NZOCIWKZUVUNDW-ZKWXMUAHSA-N Ile-Gly-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O NZOCIWKZUVUNDW-ZKWXMUAHSA-N 0.000 description 1
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 1
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000209499 Lemna Species 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- PJWDQHNOJIBMRY-JYJNAYRXSA-N Met-Arg-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PJWDQHNOJIBMRY-JYJNAYRXSA-N 0.000 description 1
- DBXMFHGGHMXYHY-DCAQKATOSA-N Met-Leu-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O DBXMFHGGHMXYHY-DCAQKATOSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- AJOKKVTWEMXZHC-DRZSPHRISA-N Phe-Ala-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 AJOKKVTWEMXZHC-DRZSPHRISA-N 0.000 description 1
- PSKRILMFHNIUAO-JYJNAYRXSA-N Phe-Glu-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N PSKRILMFHNIUAO-JYJNAYRXSA-N 0.000 description 1
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 1
- CXGLFEOYCJFKPR-RCWTZXSCSA-N Pro-Thr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O CXGLFEOYCJFKPR-RCWTZXSCSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- HBTCFCHYALPXME-HTFCKZLJSA-N Ser-Ile-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HBTCFCHYALPXME-HTFCKZLJSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XYFISNXATOERFZ-OSUNSFLBSA-N Thr-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XYFISNXATOERFZ-OSUNSFLBSA-N 0.000 description 1
- QNTBGBCOEYNAPV-CWRNSKLLSA-N Trp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O QNTBGBCOEYNAPV-CWRNSKLLSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- QPBJXNYYQTUTDD-KKUMJFAQSA-N Tyr-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QPBJXNYYQTUTDD-KKUMJFAQSA-N 0.000 description 1
- VKYDVKAKGDNZED-STECZYCISA-N Tyr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N VKYDVKAKGDNZED-STECZYCISA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000019239 indanthrene blue RS Nutrition 0.000 description 1
- UHOKSCJSTAHBSO-UHFFFAOYSA-N indanthrone blue Chemical compound C1=CC=C2C(=O)C3=CC=C4NC5=C6C(=O)C7=CC=CC=C7C(=O)C6=CC=C5NC4=C3C(=O)C2=C1 UHOKSCJSTAHBSO-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- YYVGYULIMDRZMJ-UHFFFAOYSA-N propan-2-ylsilane Chemical compound CC(C)[SiH3] YYVGYULIMDRZMJ-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 108010030651 valyl-glutamyl-prolyl-isoleucyl-prolyl-tyrosine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of protein, in particular to a bioactive polypeptide SVAPAAAGIN, a preparation method and application thereof, wherein the amino acid sequence of the bioactive polypeptide SVAPAAAGIN is Ser-Val-Ala-Pro-Ala-Ala-Ala-Gly-Ile-Asn. Through in vitro immune function regulation experiments and in vivo anti-aging experiments, the polypeptide SVAPAAAGIN is verified to have better immune function regulation and anti-aging activity, on one hand, the bioactive polypeptide SVAPAAAGIN disclosed by the invention can enhance the in vitro proliferation capacity of lymphocytes and macrophages, improve the resistance of an organism to external pathogen infection and reduce the morbidity of the organism; on the other hand, the activity of an anti-peroxidase system in vivo can be improved, and the function of resisting exogenous stimulation of an organism is enhanced, so that the probability of aging, aging and illness of the organism is reduced, and the method has very important significance for developing foods, health-care products and medicines with immunoregulation function and anti-aging function.
Description
Technical Field
The invention relates to the field of proteins, in particular to a bioactive polypeptide SVAPAAAGIN, and a preparation method and application thereof.
Background
In the process of fermenting the cow milk by the lactic acid bacteria, a part of protein in the cow milk is metabolized and utilized by the lactic acid bacteria, and a series of physiological and biochemical reactions occur, so that the protein is changed into polypeptide or free amino acid which is digested and absorbed by a human body or directly enters the blood circulation of the human body through the absorption and transportation of small intestinal epithelial cells. The lactobacillus also has some self-synthesized protein polypeptide fragments for the bacteria to grow. Among these polypeptides, some have a specific physiological function and are called "bioactive peptides".
It is particularly important to find safe bioactive peptides in natural food sources. In recent years, some food-derived polypeptides, such as short peptides of corn, soybean peptides, milk polypeptides, etc., have been found to have good biological activity. The polypeptides can be obtained through various ways such as microbial fermentation, digestion and enzymolysis and the like, and most of the polypeptides with biological activity consist of 2-20 amino acid residues, have the molecular weight of less than 6000Da and contain a certain amount of hydrophobic amino acids and aromatic amino acids.
Immunoactive peptides are a class of bioactive polypeptides that are first obtained from milk following opioid peptide discovery and demonstrate their physiological activity. Jolles et al found in 1981 for the first time that a hexapeptide with an amino acid sequence Val-Glu-Pro-Ile-Pro-Tyr can be obtained by hydrolyzing human milk protein with trypsin, and in vitro experiments prove that the hexapeptide can enhance the phagocytosis of mouse abdominal cavity macrophages to sheep erythrocytes. Migliore-Samour et al found that the casein-derived hexapeptide Thr-Thr-Met-Pro-Leu-Trp was able to stimulate phagocytosis of murine peritoneal macrophages by sheep red blood cells and to enhance resistance to Klebsiella pneumoniae. Lemna hexandra et al, fed rats with synthetic milk-derived immunoregulatory peptide (PGPIPN), found that phagocytosis of macrophages in the abdominal cavity of rats and immunoregulatory function related to erythrocytes were significantly enhanced.
Researches show that the immune active peptide can not only enhance the immunity of the organism, stimulate the proliferation of lymphocytes of the organism, enhance the phagocytic function of macrophages, promote the release of cell factors, improve the capability of the organism for resisting the infection of external pathogens, reduce the morbidity of the organism, but also can not cause the immune rejection reaction of the organism.
Aging is a natural phenomenon, and the process is often accompanied by the changes of antioxidant level, organ tissues and immune factors, wherein the cytokines are changed in a complex way, such as proinflammatory cytokines IL-6, IL-4, TNF- α and the like show a growing trend, and IL-6 and TNF-a are considered to play important roles in the process of the senile diseases.
The anti-aging peptide has the advantages that the anti-aging peptide is a novel anti-aging agent, has incomparable advantages with amino acid in the aspect of physiological function, can promote or inhibit enzymes in organisms, improve the absorption and utilization of minerals and other nutrient elements, clear away free radicals in the bodies, enhance the self anti-oxidation capability of the organisms and delay aging. Therefore, the nutrition and health care effects of bioactive peptides have become the focus of research on the subjects of scholars at home and abroad. Experiments and researches by meaningful people find that the milk-derived bioactive small peptide can effectively prolong the life of the drosophila and delay the aging of the drosophila, and has better antioxidation effect, and presumably is rich in thiopeptides. The results of Zhou Zhi Hui et al show that the bovine colostrum extract can obviously improve the SOD activity in serum of the elderly, reduce lipid peroxides of the SOD, enhance the oxidation resistance of organisms and have certain anti-aging function.
At present, there are many researches on bioactive polypeptides, for example, chinese patent CN105254738A discloses a milk-derived bioactive polypeptide DELQDKIH derived from β -casein, chinese patent CN105254739A discloses a milk-derived bioactive polypeptide GTQYTD derived from α s 1-casein, and chinese patent CN105254740A discloses a milk-derived bioactive polypeptide NQFYQKF derived from α s 2-casein.
Disclosure of Invention
The invention aims to provide a bioactive polypeptide SVAPAAAGIN, and a preparation method and application thereof.
The purpose of the invention can be realized by the following technical scheme:
in a first aspect of the invention, there is provided a biologically active polypeptide SVAPAAAGIN having an amino acid sequence Ser-Val-Ala-Pro-Ala-Ala-Ala-Gly-Ile-Asn, as shown in SEQ ID NO: 1 is shown.
Preferably, the bioactive polypeptide is derived from lactobacillus helveticus mycoprotein. Specifically from LBH-1221. sub.m.1131 LBH-1221. sub.g.1131 ORF LBH-1221. sub.g.1131 LBH-1221. sub.m.1131 type complete len:119(+) LBH-1221: 598-. LBH-1221. sub.m.1131 LBH-1221. sub.g.1131 ORF LBH-1221. sub.g.1131 LBH-1221. sub.m.1131type complete len:119(+) LBH-1221: 598-954(+) protein amino acid sequence is as shown in SEQ ID NO: 3, respectively.
The amino acid sequence of LBH _1221| m.1131 LBH _1221| g.1131 ORF LBH _1221| g.1131LBH _1221| m.1131type complete len:119(+) LBH _1221:598-954(+) protein and the corresponding nucleotide sequence are known techniques, and a fragment of nucleotides encoding amino acid residues 104 to 113 of this protein encodes the mature biologically active polypeptide SVAPAAAGIN.
Preferably, the bioactive polypeptide has an immunoregulatory function and an anti-aging function.
In a second aspect of the present invention, there is provided a nucleotide fragment encoding the biologically active polypeptide SVAPAAAGIN, the sequence of which is: 5'-ctg ttg ctc ctg cag ctg ctg gca taa att-3', as shown in SEQ ID NO: 2, respectively.
In the third aspect of the invention, the preparation method of the bioactive polypeptide SVAPAAAGIN is provided, which can be artificially synthesized by a genetic engineering method, can be directly obtained from lactobacillus helveticus thallus by a cell disruption separation and purification method, and can be directly prepared by chemical synthesis.
In the fourth aspect of the invention, the application of the bioactive polypeptide SVAPAAAGIN in preparing food, health products, medicines or cosmetics with immunoregulation function is provided.
In the fifth aspect of the invention, the application of the bioactive polypeptide SVAPAAAGIN in preparing food, health-care products or medicines with the anti-aging function is provided.
In a sixth aspect, the invention provides an application of the bioactive polypeptide SVAPAAAGIN in preparing food, health care products or medicines with immune regulation function and anti-aging function.
Specifically, the bioactive polypeptide SVAPAAAGIN of the present invention can be used for preparing cosmetics for reducing free radical damage to skin, medicines for regulating immunity and/or resisting aging; and because the product of the bioactive polypeptide SVAPAAAGIN degraded by gastrointestinal tract still has bioactivity, the bioactive polypeptide SVAPAAAGIN can be used for preparing foods such as yoghourt and the like, health-care products for regulating immunity and oral medicines for regulating immunity and/or resisting aging.
In a seventh aspect of the invention, there is provided an immunomodulatory product comprising said biologically active polypeptide SVAPAAAGIN or a derivative of said biologically active polypeptide SVAPAAAGIN; the immunoregulation product comprises immunoregulation food, immunoregulation health-care products, immunoregulation medicaments or immunoregulation cosmetics; the derivative of the biologically active polypeptide SVAPAAAGIN refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide SVAPAAAGIN.
In an eighth aspect of the invention, there is provided an anti-aging product comprising the biologically active polypeptide SVAPAAAGIN or a derivative of the biologically active polypeptide SVAPAAAGIN; the anti-aging product comprises anti-aging food, anti-aging health care product or anti-aging drug; the derivative of the biologically active polypeptide SVAPAAAGIN refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide SVAPAAAGIN.
In the ninth aspect of the present invention, a product having both immunoregulatory function and anti-aging function is provided, which comprises the bioactive polypeptide SVAPAAAGIN or a derivative of the bioactive polypeptide SVAPAAAGIN; products with immunoregulatory and anti-aging functions include foods, health products or drugs; the derivative of the biologically active polypeptide SVAPAAAGIN refers to a polypeptide derivative obtained by performing modifications such as hydroxylation, carboxylation, carbonylation, methylation, acetylation, phosphorylation, esterification or glycosylation on an amino acid side chain group, an amino terminal or a carboxyl terminal of the biologically active polypeptide SVAPAAAGIN.
The bioactive polypeptide SVAPAAAGIN has the following beneficial effects: the bioactive polypeptide SVAPAAAGIN has good activity of regulating the immunity of the organism and anti-aging activity; on one hand, the bioactive polypeptide SVAPAAAGIN can enhance the in vitro proliferation capacity of lymphocytes and macrophages, improve the capability of an organism for resisting infection of external pathogens and reduce the morbidity of the organism; on the other hand, the activity of an anti-peroxidase system in vivo can be improved, and the function of resisting exogenous stimulation of an organism is enhanced, so that the probability of aging, aging and illness of the organism is reduced, and the method has very important significance for developing dairy products and health care products with immunoregulation function and anti-aging function.
Drawings
FIG. 1: mass chromatogram extraction (m/z 870.4579);
FIG. 2: a secondary mass spectrum of a fragment with a mass to charge ratio of 870.4579;
FIG. 3: fragmentation of polypeptide az and by with mass-to-charge ratio of 870.4579;
FIG. 4: the effect of biologically active polypeptide SVAPAAAGIN on female drosophila survival;
FIG. 5: hydrogen peroxide (H)2O2) And (5) acute experiments.
Detailed Description
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples may be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples, in keeping with the knowledge of one skilled in the art and with the description of the invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, Sambrook et al: a LABORATORY MANUAL, Second edition, Cold Spring harbor LABORATORY Press, 1989and Third edition, 2001; ausubel et al, Current PROTOCOLS Inmolecular BIOLOGY, John Wiley & Sons, New York, 1987and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; wolffe, CHROMATINSTRUCUTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; (iii) Methods Inenzymolygy, Vol.304, Chromatin (P.M. Wassarman and A.P.Wolffe, eds.), academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol.119, chromatography protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999, etc.
The invention is described in detail below with reference to the figures and specific embodiments.
Example 1 Artificial Synthesis of active peptide SVAPAAAGIN
Synthesis of bioactive peptide
1. 3g of RINK resin (degree of substitution 0.3mmol/g) was weighed into a 150ml reactor and soaked with 50ml of Dichloromethane (DCM).
After 2.2 hours, the resin was washed with 3 resin volumes of N-Dimethylformamide (DMF) and then drained, and this was repeated four times and the resin was drained until use.
3. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection, the resin was washed four times with 3 resin volumes of DMF and then drained.
4. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
5. Weighing a proper amount of amino acid Ser and a proper amount of 1-hydroxy-benzotriazole (HOBT) into a 50ml centrifuge tube, adding 20ml of DMF to dissolve the amino acid Ser and the 1-hydroxy-benzotriazole (HOBT), then adding 3ml of N, N diisopropyl carbodiimide (DIC) to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor into a 30 ℃ shaking table to react.
After 6.2 hours, the column was capped with a suitable amount of acetic anhydride (acetic anhydride: DIEA: DCM ═ 1:1:2, v: v: v) for half an hour, then washed four times with 3 resin volumes of DMF and drained until needed.
7. The Fmoc protecting group on the resin was removed by adding a quantity of 20% piperidine (piperidine/DMF: 1:4, v: v) to the reactor and shaking on a decolourising shaker for 20 min. After deprotection was washed four times with DMF and then drained.
8. And (3) detecting a small amount of resin by a ninhydrin (ninhydrin) method (detecting A and B, respectively, and reacting at 100 ℃ for 1min), wherein the resin is colored, which indicates that the deprotection is successful.
9. Weighing a second proper amount of amino acid and a proper amount of HOBT in a 50ml centrifuge tube, adding 25ml of DMF to dissolve the amino acid and the HOBT, adding 2.5ml of DIC to shake and shake for 1min, adding the solution into a reactor after the solution is clarified, and then placing the reactor in a shaking table at 30 ℃ to react.
After 10.1 hours, a small amount of resin is taken for detection, and the detection is carried out by an indanthrone method (two drops are respectively detected A and B, and the reaction is carried out for 1min at 100 ℃), if the resin is colorless, the reaction is complete; if the resin is colored, the condensation is not complete and the reaction is continued.
11. After the reaction was completed, the resin was washed four times with DMF and then drained, and a certain amount of 20% piperidine (piperidine/DMF ═ 1:4, v: v) was added to the reactor, and the mixture was shaken on a decolorizing shaker for 20min to remove the Fmoc-protecting group from the resin. After the protection is removed, washing with DMF for four times, and then draining to detect whether the protection is removed.
12. The amino acids Val, Ala, Pro, Ala, Gly, Ile and Asn are sequentially grafted according to steps 9-11.
13. After the last amino acid had been grafted, the protection was removed, washed four times with DMF and the resin was drained with methanol. The polypeptide was then cleaved from the resin with 95 cleavage medium (trifluoroacetic acid: 1,2 ethanedithiol: 3, isopropylsilane: water: 95:2:2:1, v: v: v) (10 ml of cleavage medium per gram of resin) and centrifuged four times with glacial ethyl ether (cleavage medium: ethyl ether: 1:9, v: v).
To this end, bioactive peptide SVAPAAAGIN was synthesized.
Confirmation of biologically active peptides
1) UPLC analysis
UPLC conditions were as follows:
the instrument comprises the following steps: waters ACQUITY UPLC ultra-high performance liquid-electrospray-quadrupole-time-of-flight mass spectrometer
Specification of chromatographic column: BEH C18 chromatographic column
Flow rate: 0.4mL/min
Temperature: 50 deg.C
Ultraviolet detection wavelength: 210nm
Sample introduction amount: 2 μ L
Gradient conditions: solution A: water containing 0.1% formic acid (v/v), liquid B: acetonitrile containing 0.1% formic acid (v/v)
2) Mass spectrometric analysis
The mass spectrometry conditions were as follows:
ion mode: ES +
Mass range (m/z): 100-1000
Capillary voltage (Capillary) (kV): 3.0
Sampling cone (V): 35.0
Ion source temperature (. degree. C.): 115
Desolvation temperature (. degree. C.): 350
Desolventizing gas stream (L/hr): 700.0
Collision energy (eV): 4.0
Scan time (sec): 0.25
Inner scan time (sec): 0.02
According to the analysis method, the ultra-high performance liquid chromatography-electrospray-quadrupole-time-of-flight mass spectrometry is used for carrying out chromatographic analysis and mass spectrometric analysis on the bioactive peptide SVAPAAAGIN, the mass chromatogram extraction diagram is shown in figure 1, the secondary mass spectrogram of the peak and the az and by fracture conditions are shown in figures 2 and 3, the polypeptide mass-to-charge ratio of the peak is 870.4579Da, and the retention time is 48.3 min.
3) Results
As can be seen from FIG. 3, according to the cases of az and by fragmentation, the fragment sequence with mass-to-charge ratio of 870.4579Da obtained by analysis and calculation of Mascot software is Ser-Val-Ala-Pro-Ala-Ala-Gly-Ile-Asn (SVAPAAAGIN) and is marked as SEQ ID NO: 1. the fragment corresponds to the residue sequence at positions 104-113 of LBH _1221| m.1131 LBH _1221| g.1131 ORF LBH _1221| g.1131LBH _1221| m.1131type complete len:119(+) LBH _1221: 598-: 3.
example 2 experiment of the Activity of bioactive peptides in regulating the Immunity of the organism
First, MTT method for testing in vitro lymphocyte proliferation capacity experiment of bioactive polypeptide SVAPAAAGIN
1. Experimental materials and instruments:
reagents and materials: experimental animals balb/c mice (male 6-8 weeks old, animal experiment center of Shanghai university of transportation, college of agriculture and biology); the biologically active polypeptide SVAPAAAGIN obtained in example 1; mouse lymphocyte extract (ex solibao); RPMI1640 medium (purchased from GIBCO); 3- (4, 5-Dimethylthiazol-2) -2, 5-diphenyltetrazolium bromide salt (MTT, available from Amresco, Inc.); concanavalin (ConA, available from Sigma); bovine serum albumin (BSA, available from Genebase); pepsin (available from Sigma); pancreatin (Corolase PP, from AB).
The instrument equipment comprises: LRH-250F Biochemical incubator, Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge, shanghai luxiang instrument centrifuge instruments ltd; hera cell 150 CO2 incubator, Heraeus; DragonWellscan MK3 microplate reader, Labsystems corporation; ALPHA 1-2-LD vacuum freeze drier, Christ company; ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometer, waters corporation.
2. The experimental method comprises the following steps:
taking mouse spleen under aseptic condition, extracting mouse lymphocyte with lymphocyte extract, and performing primary culture. The cell density was adjusted to 2.5X 10 with complete RPMI1640 medium6one/mL. To a 96-well cell culture plate were added in sequence: 100 μ L mouse lymphocyte suspension, 100 μ L RPMI1640 complete medium, 20 μ L concanavalin, 100 μ L sample. In addition, a blank control group (PBS with pH7.2-7.4 and 3 mol/L) and a negative control group (500 mu g/mL BSA) are arranged, and the research shows that the blank control group has no influence on the in vitro lymphocyte proliferation. Each set of 3 replicates. At 5% CO2Culturing at 37 deg.C for 68h, adding 20 μ L MTT into each well under aseptic condition, culturing for 4h, carefully removing supernatant, adding 100 μ L dimethyl sulfoxide into each well, incubating at 37 deg.C for 10min, shaking, and measuring absorbance at 570nm with microplate reader.
The in vitro lymphocyte proliferation capacity is expressed by a stimulation index and is calculated as follows:
in the formula: a. the1Absorbance at 570nm for blank controlA light value; a. the2Absorbance at 570nm for the negative control, A3The absorbance at 570nm for the experimental group.
3. Experimental results and analysis:
TABLE 1 Effect of biologically active polypeptide SVAPAAAGIN on in vitro lymphocyte proliferation
Experiment grouping | Stimulation index SI |
|
1 |
SVAPAAAGIN | 1.172±0.036* |
Note: the number marked as significant difference (P <0.05) compared to the negative control.
The results are shown in Table 1. As can be seen from Table 1, under the condition that the mass concentration of the bioactive peptide SVAPAAAGIN is 100 μ g/mL, the stimulation index of the bioactive peptide SVAPAAAGIN is greater than that of BSA, which indicates that SVAPAAAGIN can stimulate the proliferation of mouse lymphocytes in vitro to some extent. And SVAPAAAGIN reached a stimulation index of 1.172, which was significantly different from that of the negative control group (P < 0.05). Therefore, the active polypeptide SVAPAAAGIN can be considered to have the capacity of remarkably promoting the mouse lymphocyte proliferation, can be eaten as a health product or an additive, and can improve the immunity of animals and human bodies.
Second, MTT method for measuring in vitro macrophage proliferation ability experiment of bioactive polypeptide SVAPAAAGIN
1) Experimental reagent and instrument
Reagent: experimental animals balb/c mice (male 6-8 weeks old) were collected at the animal Experimental center of the college of agriculture and biology of Shanghai university of transportation; the biologically active polypeptide SVAPAAAGIN obtained in example 1; 3- (4, 5-Dimethylthiazol-2) -2, 5-diphenyltetrazolium bromide (MTT) Amresco; LPS (lipopolysaccharide) Sigma company; bovine Serum Albumin (BSA) Genebase; triple solutions, aqueous solutions containing 10% SDS, 5% isobutanol and 0.012mol/L HCl.
The instrument equipment comprises: LRH-250F Biochemical incubator Shanghai Hengshi Co., Ltd; GL-22M high speed refrigerated centrifuge Shanghai Luxiang apparatus centrifuge Instrument Co., Ltd; hera cell 150 CO2Incubator Heraeus; dragon WellscanMK3 microplate reader Labsystems.
2) The test method comprises the following steps:
balb/c mice were injected intraperitoneally with 2ml of 2% (w/w) sterile starch solution for three consecutive days, and sacrificed by cervical dislocation 24 hours after the last injection. Peeling off the abdominal skin, sucking 4 ℃ Phosphate Buffer Solution (PBS) by using a syringe to repeatedly wash the abdominal cavity, centrifuging the washed solution by using a centrifuge tube for 10 minutes after collecting the washed solution, discarding the supernatant after centrifuging the washed solution (1000rpm and 4 ℃), washing the washed solution twice by using 4 ℃ RPMI1640 complete culture solution (containing 10% FBS), staining the washed solution by using 0.2% trypan blue solution to detect the vitality of the cells, and confirming that the collected viable macrophages account for more than 95%. After reading the cell counting plate, the cell concentration was adjusted to the appropriate concentration.
The cell suspension that had been blown to complete suspension was added to a 96-well cell culture plate at 37 ℃ with 5% CO in an appropriate volume2After culturing for 4 hours under the environment, removing liquid in the holes, carefully cleaning the bottom of the holes of the cell culture plate by using a complete culture solution RPMI1640 at 37 ℃, and washing the cells and cell fragments which are not attached to the walls to obtain the purified attached abdominal cavity macrophages. 0.2ml of RPMI1640 complete medium was added to each well, and the small peptide sample for experiment and LPS were dissolved in the medium in advance and then added to start cell culture.
After obtaining the purified adherent abdominal cavity macrophages, 200 mul/hole of RPMI1640 complete culture solution (10% FBS) dissolved with bioactive polypeptide SVAPAAAGIN (1mg/ml) is added into each hole of the experimental group for continuous culture for 48 h; negative control group added BSA (500. mu.g/mL) dissolved in RPMI1640 complete medium (10% FBS) 200. mu.l/well; the blank group was continuously cultured for 48 hours with the addition of 200. mu.l/well of RPMI1640 complete medium (10% FBS). In addition, the experimental group, the negative control group and the blank group are respectively provided with a normal group and an inflammation group; LPS is added into the inflammation group when the inflammation group is cultured for 24 hours until the final concentration is 100 ng/ml; LPS is not added in a normal group; and the normal group and the inflammatory group were added with 5% MTT 20. mu.l/well at 44 h; after the cell culture reached 48h, 100. mu.l/well of the triple lysis buffer was added to terminate the culture, and after overnight lysis, the absorbance value (OD570) of each well was measured by a microplate reader at a wavelength of 570nm, and the Growth index (Growth Indices) was calculated as follows:
wherein the blank culture solution is RPMI1640 complete culture solution containing 10% FBS.
3) Results and analysis of the experiments
TABLE 2 Effect of biologically active polypeptide SVAPAAAGIN on macrophage proliferation in vitro
Experiment grouping | Normal group GI | GI inflammation group |
|
1 | 1 |
SVAPAAAGIN(1mg/ml) | 1.0854±0.0612** | 1.1498±0.0264** |
Note: indicates a significant difference (P <0.05) compared to the negative control; indicates that there is a significant difference (P < 0.01) compared with the negative control group
The results are shown in Table 2, and it is understood from Table 2 that macrophages were proliferated in both the normal group and the inflammatory group in the presence of 1mg/ml of the biologically active polypeptide SVAPAAAGIN. And compared with a negative control group, the two groups have significant difference (P is less than 0.01). The result shows that the bioactive polypeptide SVAPAAAGIN has obvious proliferation effect on in vitro macrophage.
Example 3 anti-aging Activity assay of bioactive peptides
Experiment for improving survival ability of drosophila by bioactive polypeptide SVAPAAAGIN
1. Experimental reagents and instruments:
reagent: oregon K wild type drosophila melanogaster, university of shanghai transport college genetics laboratory; agar powder, national drug group chemical reagents limited; the biologically active polypeptide SVAPAAAGIN obtained in example 1.
The instrument equipment comprises: model CM-230 Mohr super Water, Shanghai Mole scientific instruments, Inc.; model G136T Zealway intelligent high temperature sterilization pot, xiamen micro instrument science and technology ltd; BJ-CD SERIES Bioincubators, Shanghai Bingbo industries, Inc.; GRX-9073 hot air sterilization cabinet, Shanghai-constant technology, Inc.
2. The experimental method comprises the following steps:
taking fruit flies as an experimental model: collecting newly emerged fruit fly imagoes within 8 hours, randomly transferring the imagoes into each experimental group after anesthesia, wherein each sex of each group is 100, each group is provided with 3 parallels, a control group is given with a common corn flour culture medium, and the experimental groups are SVAPAAAGIN bioactive peptide-corn culture media containing 0.05mg/ml, 0.5mg/ml and 1mg/ml respectively. Fresh medium was changed every 2 days, and the number of deaths of flies of different genders was observed and recorded every day until all flies died. And (4) drawing a survival curve of the fruit flies, and calculating the average life and the maximum life of the fruit flies of different sexes (taking 5 fruit flies dead finally for statistics).
3. Experimental results and analysis:
the results of the study of the life of drosophila fed with bioactive peptides of different concentrations in this experiment are as follows: from FIG. 4, it can be seen that SVAPAAAGIN fed at a concentration of 0.05mg/ml did not significantly change the survival rate of male drosophila relative to the blank control group, whereas the survival rate of female drosophila was improved at the same time point when the peptide concentration reached 0.5mg/ml and 1mg/ml, but the difference was not significant.
TABLE 3-1 SVAPAAAGIN Effect on the longevity of male Drosophila
Note: significant differences (P <0.05) in the plots compared to the placebo group; the same applies below.
TABLE 3-2 SVAPAAAGIN Effect on female Drosophila longevity
From table 3-1, it can be seen that the average life span of the male drosophila in the low dose group is not significantly changed relative to the blank control group, but the average life span of the male drosophila in the medium dose group and the high dose group is improved, namely 16.51% and 11.77% respectively, but only the medium dose group generates a significant difference (p <0.05), which indicates that the average life span of the male drosophila in the medium dose group is significantly improved. Meanwhile, the half death time of the drosophila flies in the medium-dose group and the high-dose group is improved, but no obvious difference exists in the aspect of the longest life. As can be seen from table 3-2, the low-, medium-and high-dose groups of female drosophila all improved in mean life, but did not produce significant differences. However, the longest life of both the medium and high dose groups was improved, 5 and 4 days longer than the blank control group, respectively, and a significant difference was generated (P < 0.05).
The results of this experiment demonstrate that bioactive polypeptide SVAPAAAGIN can increase the average and maximum life span of Drosophila at certain concentrations, but is related to concentration and sex. The phenomenon related to the concentration and strain of the test substance is probably because SVAPAAAGIN is involved in part of the biological metabolism of the fruit flies, or the effect of prolonging the life of the fruit flies is achieved by improving the antioxidant system of the fruit fly tissues. The metabolism of fruit flies in different strains can be differentiated, so that the results are different. The sex difference is probably because the female fruit flies have certain conservation and resistance to the external environment, so SVAPAAAGIN is not obvious in prolonging the life of the female fruit flies.
Second, experiment for improving reproductive capacity of drosophila by bioactive polypeptide SVAPAAAGIN
1. Experimental reagents and instruments:
reagent: oregon K wild type drosophila melanogaster, university of shanghai transport college genetics laboratory; agar powder, national drug group chemical reagents limited; the biologically active polypeptide SVAPAAAGIN obtained in example 1.
The instrument equipment comprises: model CM-230 Mohr super Water, Shanghai Mole scientific instruments, Inc.; model G136T Zealway intelligent high temperature sterilization pot, xiamen micro instrument science and technology ltd; BJ-CD SERIES Bioincubators, Shanghai Bingbo industries, Inc.; GRX-9073 hot air sterilization cabinet, Shanghai-constant technology, Inc.
2. The experimental method comprises the following steps:
collecting newly emerged fruit fly imago within 8 hours, separately feeding male and female, adding SVAPAAAGIN solution with concentration of 0mg/ml, 0.05mg/ml, 0.5mg/ml and 1mg/ml into the culture medium, and continuously culturing for 12 days. Adult fruit flies cultured at the same concentration were collected on day 13 and transferred to new common culture flasks, each flask holding 1 female and 2 males (5 flasks per group), each flask being given the correct 24 hours for oviposition. Transferring the parent fruit fly into a new common culture bottle after spawning, continuously breeding and culturing the old culture bottle, counting the number of offspring after the larva eclosion, continuously measuring for 7 days, and repeating for 3 times.
3. Experimental results and analysis:
TABLE 4 fertility assay results
As can be seen from table 4, the low concentration experimental group showed no significant change in the fertility compared with the control group, but the medium and high dose experimental groups showed significantly improved drosophila fertility compared with the blank control group (P < 0.05). Indicating that SVAPAAAGIN at a certain concentration can promote the reproductive capacity of fruit flies. The results of this experiment show that the prolongation of the life span of drosophila is the result of the direct action of SVAPAAAGIN, and not the secondary physiological effect of SVAPAAAGIN by reducing fertility. Meanwhile, SVAPAAAGIN is safe to fruit flies and has no toxic hazard.
Thirdly, acute oxidation experiment of hydrogen peroxide by bioactive polypeptide SVAPAAAGIN
1. Experimental reagents and instruments:
reagent: oregon K wild type drosophila melanogaster, university of shanghai transport college genetics laboratory; agar powder, national drug group chemical reagents limited; hydrogen peroxide, shanghai Lingfeng Chemicals, Inc.; the biologically active polypeptide SVAPAAAGIN obtained in example 1.
The instrument equipment comprises: model CM-230 Mohr super Water, Shanghai Mole scientific instruments, Inc.; milliporem Milllex GP0.22 μm filter membrane, Millipore, USA; GL-22M high-speed refrigerated centrifuge, Shanghai Luxiang apparatus centrifuge instruments Inc.
2. The experimental method comprises the following steps:
collecting newly emerged fruit fly imagoes within 8 hours, randomly transferring the imagoes into each experimental group after anesthesia, taking a peptide concentration culture medium with a better result in a life test, setting a blank control group and the experimental group, and giving a common corn flour culture medium to the control group. Each group of male and female sex fruit flies was 50, and the fruit flies were cultured for three weeks. Then, 5 male and 5 female fruit flies each time were transferred to a new container containing a paper disc containing 300. mu.L of a 5% sucrose solution and 1ml of 30% hydrogen peroxide, and the blank and experimental groups were exposed to the toxic peroxide environment generated by this hydrogen peroxide, and 10 replicates of each group were set up and observed for their antioxidant capacity. The number of fruit fly deaths and sex were recorded every 4 hours until all of the flies had died.
3. Experimental results and analysis:
as can be seen from fig. 5(a), for male fruit flies fed at SVAPAAAGIN, the survival rate of the male fruit flies was higher than that of the fruit flies not fed at SVAPAAAGIN at each time point, and the survival time was improved compared with that of the blank control group, indicating that the antioxidant capacity of the male fruit flies was improved after SVAPAAAGIN was fed. In fig. 5(B), the survival rate of the female fruit flies fed with SVAPAAAGIN in the high-concentration hydrogen peroxide environment for 15h is obviously higher than that of the control group, which shows that the antioxidant capacity of the female fruit flies is improved in this period. However, the survival curves of the later experimental group and the control group are basically coincident, which shows that the antioxidant capacity of the female drosophila fed with SVAPAAAGIN is gradually weakened, and the female drosophila fed with SVAPAAAGIN has no difference with the control group after a certain time. The experimental result shows that SVAPAAAGIN can improve the antioxidant capacity of fruit flies. According to H2O2As a result of acute toxicity test, it is presumed that SVAPAAAGIN might increase the H pair of fruit fly by regulating catalase CAT activity2O2Resistance to injury.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Sequence listing
<110> Zhejiang ghui peptide Life health science and technology Limited; shanghai platinum Biotech Ltd
<120> a bioactive polypeptide SVAPAAAGIN, and its preparation method and application
<160>3
<170>SIPOSequenceListing 1.0
<210>1
<211>10
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>1
Ser Val Ala Pro Ala Ala Ala Gly Ile Asn
1 5 10
<210>2
<211>30
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
ctgttgctcc tgcagctgct ggcataaatt 30
<210>3
<211>118
<212>PRT
<213> Artificial Sequence (Artificial Sequence)
<400>3
Met Arg Tyr Ile Gly Val Leu Ile Ser Gly Phe Met Ala Gly Leu Gly
1 5 10 15
Gly Ala Val Phe Ala Gln Ser Ile Ser Gly Asn Phe Ser Ile Ser Thr
20 25 30
Ile Val Gly Gln Gly Phe Ile Ala Leu Ala Ala Val Ile Phe Gly Lys
35 40 45
Trp Asn Pro Ile Gly Ala Met Leu Ser Ser Leu Phe Phe Gly Phe Ala
50 55 60
Gln Ser Leu Ser Ile Ile Gly Asn Gln Leu Pro Gly Phe Glu Lys Ile
65 70 75 80
Pro Thr Val Tyr Met Gln Ile Thr Pro Tyr Val Ile Thr Ile Val Val
85 90 95
Leu Val Ile Phe Leu Gly Lys Ser Val Ala Pro Ala Ala Ala Gly Ile
100 105 110
Asn Tyr Ile Lys Ser Lys
115
Claims (9)
1. A biologically active polypeptide SVAPAAAGIN, having an amino acid sequence Ser-Val-Ala-Pro-Ala-Ala-Ala-Gly-Ile-Asn.
2. A nucleotide fragment encoding the biologically active polypeptide SVAPAAAGIN of claim 1, wherein the nucleotide fragment has the sequence set forth in SEQ ID NO: 2, respectively.
3. The method of claim 1, wherein the biologically active polypeptide SVAPAAAGIN is synthesized by genetic engineering methods or is prepared directly by chemical synthesis.
4. The use of the biologically active polypeptide SVAPAAAGIN of claim 1, wherein the biologically active polypeptide SVAPAAAGIN is used in the preparation of a food, a health product, a pharmaceutical or a cosmetic product with immunomodulatory activity.
5. The use of the biologically active polypeptide SVAPAAAGIN of claim 1, wherein the biologically active polypeptide SVAPAAAGIN is used in the preparation of a food, a health product or a pharmaceutical product with anti-aging properties.
6. The use of the biologically active polypeptide SVAPAAAGIN of claim 1, wherein the biologically active polypeptide SVAPAAAGIN is used in the preparation of a food, a health product or a pharmaceutical product with immunomodulatory and anti-aging effects.
7. An immunomodulatory product comprising the biologically active polypeptide SVAPAAAGIN of claim 1; the immunoregulation product comprises an immunoregulation food, an immunoregulation health product, an immunoregulation medicament or an immunoregulation cosmetic.
8. An anti-aging product comprising the biologically active polypeptide SVAPAAAGIN of claim 1; the anti-aging product comprises anti-aging food, anti-aging health care products or anti-aging drugs.
9. A product having immunomodulatory and anti-aging properties, comprising the biologically active polypeptide SVAPAAAGIN of claim 1; the product with immunoregulation function and anti-aging function comprises food, health product or medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810717782.9A CN108794604B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810717782.9A CN108794604B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108794604A CN108794604A (en) | 2018-11-13 |
CN108794604B true CN108794604B (en) | 2020-02-07 |
Family
ID=64074548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810717782.9A Active CN108794604B (en) | 2018-06-29 | 2018-06-29 | Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108794604B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112679598A (en) * | 2021-01-19 | 2021-04-20 | 浙江辉肽生命健康科技有限公司 | Bioactive peptide SGVSLAALKKALAAAGYDVEK, and preparation method and application thereof |
CN116444611A (en) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | Milk active peptide TDPLFKG, preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009121176A1 (en) * | 2008-03-31 | 2009-10-08 | The University Of British Columbia | Insulin-induced gene (insig) peptide compositions and methods for cytoprotection |
CN105254750B (en) * | 2015-10-16 | 2019-01-08 | 浙江辉肽生命健康科技有限公司 | A kind of biologically active polypeptide FGYSGAFKCL and its preparation and application |
-
2018
- 2018-06-29 CN CN201810717782.9A patent/CN108794604B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108794604A (en) | 2018-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108794598B (en) | Bioactive polypeptide NARIQDNLYLAV, and preparation method and application thereof | |
CN109160944B (en) | Bioactive polypeptide ATAVPIIFF, and preparation method and application thereof | |
CN107226857B (en) | Bioactive polypeptide TIASGEPT and preparation method and application thereof | |
CN107163136B (en) | Bioactive polypeptide WNIPMGLIVNQ, and preparation method and application thereof | |
CN107236031B (en) | Bioactive polypeptide PMIGVNQELAY, and preparation method and application thereof | |
CN109053868B (en) | Bioactive polypeptide DIENIKITGEI, and preparation method and application thereof | |
CN108794593B (en) | Bioactive polypeptide GSVNDVQ and preparation method and application thereof | |
CN108997483B (en) | Bioactive polypeptide DQDLVLI and preparation method and application thereof | |
CN108794590B (en) | Bioactive polypeptide EPGIVNLD and preparation method and application thereof | |
CN107814839A (en) | A kind of biologically active polypeptide PIGSENSEKTTMPL and its preparation method and application | |
CN108794602B (en) | Bioactive polypeptide PNIMVIQH and preparation method and application thereof | |
CN107840880A (en) | A kind of biologically active polypeptide GLNYYQQKPVA and its preparation method and application | |
CN108794604B (en) | Bioactive polypeptide SVAPAAAGIN, and preparation method and application thereof | |
CN110922466A (en) | Bioactive polypeptide KSWNETFHARLA, and preparation method and application thereof | |
CN108558991B (en) | Bioactive polypeptide GIQDPKEP and preparation method and application thereof | |
CN108341855A (en) | A kind of biologically active polypeptide ADVKIGNDTVIEGN and its preparation method and application | |
CN108794605B (en) | Bioactive polypeptide SRPETSG, and preparation method and application thereof | |
CN108794600B (en) | Bioactive polypeptide SNLIEVT and preparation method and application thereof | |
CN108017707B (en) | Bioactive polypeptide QPVLGPVRGP, and preparation method and application thereof | |
CN107903316B (en) | Bioactive polypeptide LPYPYYA and preparation method and application thereof | |
CN108794603B (en) | Bioactive polypeptide TVTMLMTTIL, and preparation method and application thereof | |
CN107880107B (en) | Bioactive polypeptide QVLSNTVPA, and preparation method and application thereof | |
CN108794595B (en) | Bioactive polypeptide IYQVHA and preparation method and application thereof | |
CN108794588B (en) | Bioactive polypeptide FDPTLHQ and preparation method and application thereof | |
CN108822193B (en) | Bioactive polypeptide VMTMLDK and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |